By Helena Smolak
Valneva expects further sales growth this year after it posted higher revenue in 2024.
The French vaccine company said Tuesday that it expects total revenue in 2025 to grow to between 180 million euros and 190 million euros ($188.7 million and $199.2 million) with a positive cashflow. It expects to reach R&D investments of between 90 million and 100 million euros for this year.
Its full-year revenue rose 10% to 169.6 million euros despite lower-than anticipated sales of its attenuated chikungunya vaccine in the U.S.
Its cash and cash equivalents stood at 168.3 million euros as of Dec. 31.
The company will publish its audited full-year results on Mar. 20.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
February 18, 2025 03:13 ET (08:13 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.